Live Updates > Live Update Details
2025-09-18 05:14:43
According to media reports, Novo Nordisk has submitted a new drug application for marketing approval, which will be reviewed by the U.S. Food and Drug Administration (FDA) before the end of the year. The oral version of its weight loss drug, Wegovy, has shown similar efficacy to its injectable counterpart in weight loss trials. In a newly published study, Novo Nordisk's oral semaglutide 25 mg (WEGOVY® tablets*) achieved a 16.6% weight loss in obese people. The 25 mg oral version also demonstrated improvements in the ability to perform daily physical activities and cardiovascular risk factors, with a safety and tolerability profile consistent with the injectable version of Wegovy.
